Posted by Michael Wonder on 02 May 2024
ICER to assess treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
2 May 2024 - Report will be subject of New England CEPAC meeting in November 2024; draft scoping document open to public comment until 22 May 2024.
The ICER announced today that it will assess the comparative clinical effectiveness and value of tabelecleucel (Pierre Fabre) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.
